1Pfreundschuh M, Trfimper L, Osterborg A,et al. CHOP-like chemotherapy plus rimximab versus CHOP-like ehemotler pyalone in young patients with good-prognosis diffuse large B-cell lymphoma:a randomised controlled trial bythe Mab Thera International Trial (MINT) Group[J]. Lancet Oncol, 2006,7(5) : 379-391.
2Glass B,Kloess M,Bentz M,et al. Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplanration for primary treatment of aggressive high-risk non-Hodgkin Lymphoma[J]. Blood, 2006,107(8) : 3058-3064.
4Jermann M,Jost L M,Tavema C H, et al. Rituximab-EPOCH, an efective salvage therapy for relapsed, refractory or transformed B- cell lymphomas: results of a phase Ⅱ study[J]. Ann Oncol,2004, 15(3) :511-516.
7Coiffier B, Lepage E, Briere J,et al. CHOP chemotherapy plus ritux-imab compared with CHOP alone in elderly patients with diffuselarge-B-cell lymphoma[J]. N Engl J Med, 2002,346 (4) : 235.
3[1]Mohammad RM,Wall N R,Dutcher J A,et al.The addition of bryostatin 1 to cyclophosphamide,doxorubicin,vincristine,and prednisone (CHOP) chemotherapy improves response in a CHOP resistant human diffuse large cell lymphoma xenograft model[J].Clin Cancer Res,2000,6(12):4950-4956.
4[2]Golay J T,Clark E A,Beverley P C,et al.The CD20 (Bp35) antigen is involved in activation of B cells from the GO to the G1 phase of the cell cycle[J].J Immunol,1985,135(6):3795-3801.
5[3]Stashenko P,Nsdler L M,Hardy R,et al.Characterization of a human B lymphocyte-specific antigen[J].J Immunol,1980,125(7):1678-1685.
6[4]Stashenko P,Nsdler L M,Hardy R,et al.Expression of cell surface markers after human B lymphocyte activation[J].Proc Natl Acad Sci USA,1981,78(3):3848-3852.
7[5]Press O W,Farr A G,Ingrid Borroz K,et al.Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies[J].Cancer Res,1989,49(6):4906-4908.
8[6]Shan D,Ledbetter J A,Press O W,et al.Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies[J].Blood,1998,91(5):1664-1652.
9Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma [J]. N Engl J Med, 1993,328 (14) : 1002-1006.
10Cheson BD, Homing S J, Coiffier B, et al. Report of an international workshop to standardize response criteria for nonHodgkin's lymphoma [J]. J Clin Oncol, 1999,17 : 1244-1253.
